http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Angelo Lozada ),( Catherine Teh ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: A variety of clinical and biochemical factors have been proposed to predict liver fibrosis. Some of these entail high cost and are impractical in the 3rd world setting. Thus, the aim of this study is to determine of body mass index (BMI) predectis the severity of liver fibrosis as assessed by Transient Elastography (TE, Fibroscan®), seen in a local liver clinic. Methods: From 3207 patients seen at the Makati Medical Center Liver Clinic from Jan 2010 to Feb 2016 with various liver diseases, a total of 388 were enrolled into the study. Initial BMI and liver stiffness measurements (LSM) were obtained and subsequently followed up after patient education about lifestyle modification. Results: Out of the 388 patients studied, the ratio of males to females was 1:1. The mean age was 53.27±12.3 years. The most common indication for TE was a diagnosis of non-alcoholic fatty liver disease (NAFLD) at 56.7%; followed by mixed liver disease, 39.5%; Hepatitis B, 3%; and Hepatitis C, 0.7%. Subsequent follow up showed no change in patients’ BMI (26.7±3.68 vs 26.5±3.52, P>0.05). Likewise there was a positive correlation between the BMI and the LSM (P<0.05). Conclusions: Our results showed that BMI may be a useful predictor of severity of fibrosis in patients with liver disease in the 3rd world setting where cost of fibrosis testing maybe prohibitive. This study likewise shows that patient education is a key factor in the reversal of fibrosis and that efforts to emphasize this are lacking.
( Pil Soo Sung ),( Eun Byul Lee ),( Dong Jun Park ),( Angelo Lozada ),( Jeong Won Jang ),( Si Hyun Bae ),( Jong Young Choi ),( Seung Kew Yoon ) 대한간학회 2018 Clinical and Molecular Hepatology(대한간학회지) Vol.24 No.3
Background/Aims: Hepatitis C virus (HCV) replicates in the peripheral blood mononuclear cells (PBMCs), leading to the production of type I interferons (IFNs). It is well known that the gene expression profile of PBMC is similar to that of the liver. The present study explored the dynamic gene expression profile of PBMCs collected from HCV-infected patients undergoing direct-acting antiviral (DAA) therapy. Methods: A prospective cohort comprising 27 patients under DAA therapy was formed. Expression level of IFN-β and its downstream interferon-stimulated genes (ISGs) was measured in PBMCs before and after DAA treatment. Furthermore, immunoblotting was performed to identify the signaling molecules involved in the expression of ISGs. Results: The pretreatment expression level of interferon-induced protein 44 (IFI44) and C-X-C motif chemokine ligand 10 (CXCL10) correlated with the pretreatment expression level of IFN-β. After DAA treatment, a significant decrease in the expression levels of IFN-β, IFI44, and CXCL10 was observed in the PBMCs. Furthermore, the pretreatment expression level of IFN-β and ISGs correlated with the level of signal transducer and activator of transcription 1 (STAT1) phosphorylation, and DAA treatment abrogated STAT1 phosphorylation. Conclusions: Pretreatment activation of IFN-β response is rapidly normalized after DAA treatment. The present study suggests that the decreased type I IFN response by the clearance of HCV might contribute to DAA-induced alleviation of extrahepatic manifestation of chronic HCV infection. (Clin Mol Hepatol 2018;24:302-310)
양현,우현영,이순규,한지원,장보현,남희철,이해림,이성원,송도선,송명준,오정석,천호종,장정원,Angelo Lozada,배시현,최종영,윤승규 대한간학회 2017 Clinical and Molecular Hepatology(대한간학회지) Vol.23 No.2
Background/Aims: Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). Methods: A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS. Results: The median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (P=0.029). The Cox proportional-hazard model showed that a higher risk of death was correlated with higher serum alpha fetoprotein level (≥400 mg/dL, hazard ratio [HR]=1.680, P=0.014) and Child-Pugh class B (HR=1.856, P=0.008). Conclusions: MET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.